Browse TYMP

Summary
SymbolTYMP
Namethymidine phosphorylase
Aliases gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF02885 Glycosyl transferase family
PF00591 Glycosyl transferase family
PF07831 Pyrimidine nucleoside phosphorylase C-terminal domain
Function

May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro. ; FUNCTION: Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0006206 pyrimidine nucleobase metabolic process
GO:0006213 pyrimidine nucleoside metabolic process
GO:0008655 pyrimidine-containing compound salvage
GO:0009112 nucleobase metabolic process
GO:0009116 nucleoside metabolic process
GO:0009163 nucleoside biosynthetic process
GO:0009164 nucleoside catabolic process
GO:0019439 aromatic compound catabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0043094 cellular metabolic compound salvage
GO:0043097 pyrimidine nucleoside salvage
GO:0043174 nucleoside salvage
GO:0044270 cellular nitrogen compound catabolic process
GO:0046134 pyrimidine nucleoside biosynthetic process
GO:0046135 pyrimidine nucleoside catabolic process
GO:0046700 heterocycle catabolic process
GO:0048514 blood vessel morphogenesis
GO:0072527 pyrimidine-containing compound metabolic process
GO:0072528 pyrimidine-containing compound biosynthetic process
GO:0072529 pyrimidine-containing compound catabolic process
GO:1901136 carbohydrate derivative catabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1901657 glycosyl compound metabolic process
GO:1901658 glycosyl compound catabolic process
GO:1901659 glycosyl compound biosynthetic process
Molecular Function GO:0004645 phosphorylase activity
GO:0008083 growth factor activity
GO:0009032 thymidine phosphorylase activity
GO:0016154 pyrimidine-nucleoside phosphorylase activity
GO:0016757 transferase activity, transferring glycosyl groups
GO:0016758 transferase activity, transferring hexosyl groups
GO:0016763 transferase activity, transferring pentosyl groups
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00240 Pyrimidine metabolism
hsa00983 Drug metabolism - other enzymes
hsa01100 Metabolic pathways
Reactome R-HSA-1430728: Metabolism
R-HSA-15869: Metabolism of nucleotides
R-HSA-73621: Pyrimidine catabolism
R-HSA-73848: Pyrimidine metabolism
R-HSA-73614: Pyrimidine salvage reactions
Summary
SymbolTYMP
Namethymidine phosphorylase
Aliases gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TYMP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TYMP and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16497972Plasma Cell MyelomaInhibit immunityIdentification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. We isolated tumor-reactive cytotoxic CD8(+) T-cell (CTL) clones from a patient successfully treated with donor lymphocyte infusion for relapsed multiple myeloma after allogeneic HLA-matched SCT. Because solid tumors expressing ECGF-1 could also be lysed by the CTL, ECGF-1 is an interesting target for immunotherapy of both hematologic and solid tumors.
Summary
SymbolTYMP
Namethymidine phosphorylase
Aliases gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TYMP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTYMP
Namethymidine phosphorylase
Aliases gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TYMP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5510.317
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8050.796
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3590.871
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2120.652
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1940.938
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2390.942
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3110.538
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3460.811
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1970.908
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.260.569
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4620.894
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0630.748
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TYMP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTYMP
Namethymidine phosphorylase
Aliases gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TYMP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTYMP
Namethymidine phosphorylase
Aliases gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TYMP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TYMP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTYMP
Namethymidine phosphorylase
Aliases gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TYMP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTYMP
Namethymidine phosphorylase
Aliases gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TYMP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTYMP
Namethymidine phosphorylase
Aliases gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TYMP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTYMP
Namethymidine phosphorylase
Aliases gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TYMP collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TYMP.
ID Name Drug Type Targets #Targets
DB09343TipiracilSmall MoleculeTYMP1